

ASX ANNOUNCEMENT 23 NOVEMBER 2023

# POSITIVE IN VITRO DATA FOR CHM 1301 CAR NK CELLS IN OVARIAN AND PANCREATIC CANCERS

- Positive preclinical data for CHM 1301, a next generation off the shelf CLTX CAR NK cell therapy
- Up to 300% enhanced cell killing demonstrated compared to first generation NK cells
- Evidence of expansion into two new solid tumours pancreatic cancer and ovarian cancer
- CHM 1301 program to advance to the next stage of preclinical development under academic research collaboration

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce positive in vitro data for CHM 1301, its next generation chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy program.

CHM 1301 demonstrates the synergies of assets in the Chimeric portfolio, as it combines the recently announced efficacy of CHM 1101, Chimeric's CLTX CAR T cell therapy<sup>1</sup>, with the efficacy and off-the-shelf convenience of CHM 0201<sup>2</sup>, Chimeric's NK cell platform, to create a next generation CLTX CAR NK cell therapy.

CHM 1301 was studied in preclinical in vitro models of human ovarian cancer and pancreatic cancer, demonstrating highly promising efficacy. In ovarian cancer, cell killing was increased up to ~260% as compared to first generation CHM 0201 cells, while in pancreatic cancer cell killing was increased up to 300% as compared to first generation CHM 0201 cells.

The expansion into these new disease areas demonstrates the potential of Chimeric's CLTX CAR therapies to address additional high-unmet need solid tumour types beyond glioblastoma.

Based on the success of these studies, Chimeric is advancing the CHM 1301 program to the next stage of preclinical development using Chimeric's recently developed armoured NK cell platform (CHM 0301), to further enhance cell potency and resistance against the immunosuppressive solid tumor microenvironment.

"We are very pleased with the rapid success being shown with our next generation CHM 1301 platform. We believe this work is highly impactful as it demonstrates the synergy of the assets that currently exist in Chimeric's portfolio, the ability for Chimeric to expand into new disease areas and the potential for enhanced efficacy with an off the shelf version of our CHM 1101 CAR," said Jennifer Chow, CEO and Managing Director, Chimeric Therapeutics. "Being able to achieve this success through our cost effective, academic collaboration with Dr David Wald at Case Western Reserve University also enables Chimeric to continue to build out a promising next generation pipeline while focusing resources on our current clinical stage assets."



#### **BACKGROUND:**

CHM 1101, Chimeric's CLTX CAR T cell therapy, is a personalized cell therapy that recently demonstrated positive Phase 1A clinical data in late-stage glioblastoma patients<sup>1</sup>. As a personalized cell therapy CHM 1101 is manufactured by combining the CHM 1101 CAR construct with an individual patient's own T cells.

CHM 0201, Chimeric's NK cell platform, is an off-the-shelf cell therapy that demonstrated positive Phase 1A clinical data in colorectal cancer and acute myeloid leukemia patients in 2022<sup>2</sup>. As an off-the-shelf cell therapy CHM 0201 is manufactured utilizing a healthy donors' NK cells allowing for large numbers of cells to be frozen and made readily available for patients on demand.

CHM 1301, is an off-the-shelf CAR NK cell therapy that combines the efficacy of CHM 1101 with the efficacy and off-the-shelf convenience of CHM 0201. CHM 1301 is manufactured by combining the CHM 1101 CLTX CAR construct with a healthy donors' NK cells, providing an off the shelf CLTX CAR NK cell therapy option for patients.

- 1. Chimeric Therapeutics ASX Announcement, October 22, 2023, "Positive Preliminary Phase 1A Data for CLTX CAR T in Recurrent Brain Cancer Clinical Trial"
- Otegbeye F, et al. A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. Transplant Cell Ther. 2022;28(5):250.e1-250.e8. doi: 10.1016/j.jtct.2022.02.008

### **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.



CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the worldrenowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

#### **CONTACT**

## **Investors**

Jennifer Chow **Chimeric Therapeutics** 

T: + 1 9087238387

E: jchow@chimerictherapeutics.com W: www.chimerictherapeutics.com

**Chimeric Therapeutics** 

**Paul Hopper** 

T: + 61 406 671 515

E: paulhopper@lifescienceportfolio.com

#### Media

Matthew Wright **NWR Communications** P: +61 451 896 420

E: matt@nwrcommunications.com.au